Similar articles

• Influence of autoantibodies against AT1 receptor and AGTR1 polymorphisms on candesartan-based antihypertensive regimen: results from the study of optimal treatment in hypertensive patients with anti-AT1-receptor autoantibodies trial.

  Sun Y, Liao Y, Yuan Y, Feng L, Ma S, Wei F, Wang M, Zhu F. Sun Y, et al. J Am Soc Hypertens. 2014 Jan;8(1):21-7. doi: 10.1016/j.jash.2013.08.002. Epub 2013 Oct 13. J Am Soc Hypertens. 2014. PMID: 24131669
• [AT1 receptor autoantibodies and essential hypertension].

  Liu H, Yang Y, Chen LL. Liu H, et al. Hunan Yi Ke Da Xue Xue Bao. 2003 Jun;28(3):255-8. Hunan Yi Ke Da Xue Xue Bao. 2003. PMID: 14653082 Clinical Trial. Chinese.
• Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.

  Wei F, Jia XJ, Yu SQ, Gu Y, Wang L, Guo XM, Wang M, Zhu F, Cheng X, Wei YM, Zhou ZH, Fu M, Liao YH; SOT-AT1 Study Group. Wei F, et al. Heart. 2011 Mar;97(6):479-84. doi: 10.1136/hrt.2009.192104. Epub 2011 Feb 4. Heart. 2011. PMID: 21296780 Clinical Trial.
• The Role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia.

  Campbell N, LaMarca B, Cunningham MW Jr. Campbell N, et al. Curr Pharm Biotechnol. 2018;19(10):781-785. doi: 10.2174/1389201019666180925121254. Curr Pharm Biotechnol. 2018. PMID: 30255752 Free PMC article. Review.
• AT1 receptor agonistic antibodies, hypertension, and preeclampsia.

  Dechend R, Müller DN, Wallukat G, Homuth V, Krause M, Dudenhausen J, Luft FC. Dechend R, et al. Semin Nephrol. 2004 Nov;24(6):571-9. doi: 10.1016/s0270-9295(04)00128-7. Semin Nephrol. 2004. PMID: 15529292 Review.